Evidence-based behaviour change techniques to aid smoking cessation for pregnant women with mental illness: a systematic review Authors: Ellie Jones, Amelia Casey, Christine MacArthur, Beck Taylor, Tim Coleman Published: 2026 ABSTRACT AbstractBackgroundSmoking during pregnancy is the leading preventable cause of maternal and infant morbidity and mortality in high income countries, disproportionately affecting women with mental illness. While behavioural smoking cessation interventions are effective for pregnant women and non-pregnant people with mental illness separately, evidence for specific smoking cessation interventions for pregnant women with mental illness is lacking. This review aimed to identify and map BCTs from effective general mental health smoking cessation trials to determine which may be helpful for pregnant women experiencing mental illness.MethodsA systematic review identified effective smoking cessation RCTs among people with mental illness. MEDLINE, EMBASE, PsycINFO, CINAHL, HMIC and CENTRAL databases were searched through April 2026. BCTs were coded using BCT Taxonomy; those in at least two effective interventions classified as ‘promising’ and compared against BCTs identified within National Centre for Smoking Cessation Training Standard Treatment Programme for pregnant women.ResultsOf 12,403 records, 195 full texts were screened and 16 RCTs met the inclusion criteria. Most interventions combined psychosocial and pharmacological components; motivational interviewing was the most common. Of 39 distinct BCTs identified, 26 were ‘promising’. Frequent BCTs included goal setting (1.1), problem solving (1.2), action planning (1.4), social support (unspecified) (3.1), instruction on how to perform the behaviour (4.1) and pharmacological support (11.1). High overlap exists; most promising BCTs for mental health populations are already embedded within the standard UK pregnancy care pathway.ConclusionsThis study shows that behavioural components of effective smoking cessation interventions for people experiencing mental illness align with what is available women accessing NHS smoking in pregnancy cessation services. However, persistently high smoking rates in pregnant women with mental illness suggest that the presence of these techniques alone is insufficient. These findings imply that service improvements should prioritise adapting the delivery of existing BCTs, such as goal setting and problem-solving, to address specific psychological barriers and social contexts of this group to improve engagement and clinical outcomes.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12884-026-09347-z.Keywords: Smoking cessation, Perinatal mental health, Behaviour change, Pregnancy Background Smoking in pregnancy remains a leading preventable cause of maternal and infant mortality and morbidity in the UK and other developed countries [1–3] and remains a major public health concern [4]. Pregnant women who smoke are twice as likely to experience a stillbirth, miscarriage and sudden infant death syndrome [5–7]. Smoking during pregnancy is associated with increased risk of low birthweight, children developing respiratory conditions, attention and hyperactivity disorders, learning disabilities, ear, nose and throat problems, obesity, diabetes and becoming smokers themselves [8–18]. Smoking in pregnancy is a significant health inequality [19], including for women with mental illness. Cohort data from England suggests nearly one in four pregnant smokers has a diagnosed mental disorder [20] and whilst these women are more likely to accept cessation referrals than those without mental illness (69% vs. 56%), they are significantly less likely to successfully quit by time of birth [20], a pattern also observed beyond the UK. Studies from the United States of America report smoking prevalence rates of 27–33% among pregnant women with depression or anxiety compared to 10–13% without [21, 22], with almost half of pregnant smokers meeting criteria for at least one mental disorder [21]. Consistently lower quit rates have also been observed among pregnant women with mental illness who are smokers (48% compared to 62%) [23], suggesting unmet need and additional barriers beyond motivation and support that may contribute to persistence of smoking. A Cochrane review of non-pharmacological interventions for smoking cessation during pregnancy (any pregnant women) has shown several methods are effective [24]. Compared with usual care, counselling increased smoking cessation in late pregnancy (risk ratio (RR) 1.44, 95% CI 1.19–1.73), incentive-based interventions were effective when compared with non-contingent incentive (RR 2.36, 95% CI 1.36–4.09), feedback provided in conjunction with counselling increased smoking cessation when compared with usual care (RR 4.39, 95% CI 1.89–10.21). Similarly, non-pharmacological interventions were also effective in supporting smoking cessation for people (not specifically pregnant) with mental illness. A recent review found evidence of effectiveness for bespoke face-to-face interventions compared with usual care at (medium-term (up to 6 months) RR 2.29, 95% CI 1.38,3.81; long-term (> 6 months): RR 1.58, 95% CI 1.09,2.30) [25]. Although non-pharmacological interventions for smoking cessation have been shown to be effective for both non pregnant people experiencing mental illness and for pregnant women as separate populations, no evidence exists on which intervention components may be most beneficial for pregnant women who have mental illness. Trials of smoking cessation interventions for people with mental illness typically exclude pregnant women [26, 27] while pregnancy specific trials rarely provide subgroup analyses for this population [24]. Consequently, it remains unclear which behavioural components and behaviour change techniques are most effective or appropriate for use during pregnancy among women with mental illness. Currently, the National Centre for Smoking Cessation and Training (NCSCT) Standard Treatment Programme (STP) for pregnant women represents the standard behavioural support available in the UK. However, this standard programme does not currently include specific components tailored to the unique barriers faced by pregnant women with mental illness. Given that trials specifically targeting pregnant women with mental illness are lacking, the next logical next step was to examine the wider evidence base for smoking cessation in people with mental illness as potentially effective BCTs identified in this wider population could be adapted and added to the existing NCSCT STP. Hence, this systematic review aimed to identify behavioural intervention components and BCTs used in effective smoking cessation trials for people with mental illness. These were then compared to the NCSCT STP to determine their potential for adaptation and integration into standard pregnancy care to better support women with mental illness. Methods The protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO 1030965) and is based on the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol (PRISMA-P) guideline [28]. Covidence systematic review software [29] was used for the title and abstract screening and Microsoft Excel [30] used for data extraction and analysis. Behavioural interventions are typically multifaceted, so distinguishing their active ingredients requires a standardised, theory-driven framework. Michie and colleagues developed the BCT taxonomy v1 [31, 32] and proposed that by identifying individual BCTs within interventions, it is possible to specify how interventions operate and therefore what components might be incorporated into new and more effective interventions [31]. This methodology has been used to specify evidence-based BCTs within smoking cessation interventions for the general population [33–35], preventing relapse following stay in smoke free settings [36, 37], during pregnancy [38, 39] and reducing environmental tobacco smoke exposure [40]. Eligibility criteria Participant types Eligible studies included adults with mental illness who smoke including people with schizophrenia or other psychotic disorders, depression, anxiety (including post-traumatic stress disorder and obsessive compulsive disorder), personality disorders and eating disorders. Intervention types Eligible studies included those that described or evaluated a behavioural intervention to support smoking cessation. The definition of behavioural interventions was based on Spanakis et al. [25]: a structured program or strategy designed to influence or change specific behaviours through psychological, social, or environmental means rather than by pharmacological methods. Interventions could be delivered face-to-face or remotely, digital or group based. Trials that used electronic cigarettes or adjunctive pharmacotherapy alongside a behavioural programme were eligible for inclusion. Solely pharmacotherapeutic trials were excluded as the focus was to identify components of effective psychosocial interventions which may be beneficial for pregnant women. Comparator types Eligible studies were those with an alternative smoking cessation intervention, usual care or no intervention. Outcomes Eligible studies were those that reported a statistically significant difference (P < 0.05) in biochemically verified 7-day point prevalence abstinence (including carbon monoxide, salivary cotinine, urinary cotinine or serum cotinine) at any time point. Study types Randomised Controlled Trials RCTs (including individually randomised and cluster RCTS. Exclusion criteria Trials were excluded if they did not show a statistically significant between-group difference on biochemically 7-day point prevalence abstinence. Studies not in English language were also excluded due to detailed intervention information required to label the BCTs using the BCT taxonomy and high precision needed for this. Non-randomised studies were also excluded to risk of performance and selection bias [41]. Search strategy The search strategy was adapted from an existing review of behavioural smoking cessation interventions for people with mental illness [25] (Additional File 1). Spanakis et al. [25] provided important evidence on intervention effectiveness but did not examine the specific BCT components. The present review extends this work by applying the BCT Taxonomy v1 to identify and categorise the active ingredients of effective interventions. To ensure relevance to perinatal populations, additional terms were added to include other mental health conditions commonly experienced by women who use perinatal mental health services but excluded from Spanakis et al. [25], such as anxiety and post-traumatic stress disorder. These additions reflect qualitative evidence highlighting the mental health illnesses most relevant to pregnant women who smoke [42]. MEDLINE, EMBASE, PsycINFO, CINAHL, Health Management Information Consortium and CENTRAL databases were searched on February 2025. Reference lists of all eligible studies, existing reviews and trial registries were also checked and supplemented by grey literature searches for relevant studies. Conference abstracts were subsequently checked to see if full papers had been published. Two researchers screened titles and abstracts independently. Any disagreements were resolved by consensus, consulting two additional authors where necessary. The searches were updated in April 2026 were reviewed by one researcher and discussed with all authors. Data extraction Relevant primary study characteristics data were extracted independently by two researchers who were trained in the BCT taxonomy using a pre-defined data extraction form (Additional File 2). To ensure any relevant BCTs were captured, the following coding principles were followed: BCTs which were definitely coded were given (++) and probably coded were given (+) (www.bct-taxonomy.com). Any discrepancies were resolved through discussion. An artificial intelligence (AI) programme, ChatGPT (OpenAI, GPT-4, 2025) was also used as exploratory tool for extracting and labelling behaviour change techniques (BCTs). Prompts were designed to elicit standardised BCT labels according to the BCT Taxonomy v1. The use of AI assistance was exploratory and supplemented standard manual coding processes by the two researchers. Data analysis Primary studies were categorised into three groups: behavioural intervention only, behavioural intervention with pharmacotherapy commonly used for smoking cessation in pregnancy and behavioural intervention with pharmacotherapy not used in pregnancy. Frequency counts of BCTs present across trials were conducted. A list of ‘promising’ BCTs most likely to be effective in supporting smoking cessation in people with mental illness was created. A BCT was classified as ‘promising’ if it featured in at least two interventions included in the review, to identify techniques that work across different settings and populations, as described in other studies using similar methods [38, 40, 43]. To compare the list of promising BCTs to the NCSCT standard treatment programme (STP) for pregnant women, firstly the STP was screened for BCTs using the methods described above. The list of promising BCTs from primary studies were then compared to the BCTs identified in the NCSCT STP for pregnant women. One researcher independently assessed risk of bias using the Cochrane risk of bias 2 tool [44]. Risk of bias was categorised as high, low, or unclear for the following domains: ‘random sequence generation’, ‘allocation concealment’, ‘blinding of participants and personnel’, ‘incomplete outcome data’, ‘blinding of outcome assessment’, and for any other bias (e.g., funding) in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [45]. Results The search identified 12,403 records, of which 195 full texts were screened for eligibility. Of these, 16 studies were discussed with two additional authors to determine whether they met criteria for inclusion (Fig. 1). A total of 16 studies met the inclusion criteria (Table 1). All studies were individually randomised controlled trials, although three studies were pilot randomised controlled trials [46–48]. Eleven studies were undertaken in United States of America [47–57], three in Australia [58–60] and two in the United Kingdom [27, 46]. PRISMA flow chart Table 1Characteristics of included studiesAuthor, YearStudy Design, country, population, participantsIntervention/control descriptionSmoking outcome measuresMain findings Baker 2006 [60]RCTSyndey and Newcastle, Australia.Smokers > 18yrs, smoking > 15 cigarettes/day with non-acute psychotic disorder residing in the community with interest in quitting smokingTotal: 298I:147C: 151I: x8 individual 1-hour sessions of motivational interviewing and CBT + NRT +treatment as usual and booklet on SCC: Treatment as usual: booklets on SC, access to GPs and publicly funded mental health teams.Therapy delivered by trained therapist• Biochemically verified (BV) Point prevalence abstinence (PPA)* @ 3, 6 and 12 months• Continuous abstinence (3,6 and 12months)• Smoking reduction (reduction of daily consumption of cigarettes by 50% or greater (incl. abstinence) relative to baseline• Fagerstrom Test for Nicotine Dependence• Motivation to Quit smokingPPA @ 3 months:I:15% C:6% (OR 2.78 99% CI 1.78,24.41)PPA @ 6 months:I:9.5% C: 4.0% OR2.54 (99% CI 0.70,9.28)PPA @ 12 months:I:10.9%, C: 6.6% 1.72 (99% CI 0.58, 5.09)Continuous abstinence @3 monthsI: 10.9%C:4% OR 2.95, 95% CI, 0.83,10.53)CA @6 months:I: 5.4C:2.0 OR 2.84 (95% CI 0.48,16.67)CA at 12months:I: 0.7C: 3.4 (OR 5.28 (95% CI 0.31, 90.20)Smoking reduction of 50% or > relative to baseline:3 months:I:43.5%C:16.6% (OR 3.89, 95% CI 1.91,7.89)6 months:I:29.9%C:18.5% (OR 1.88, 95% CI 0.92,3.82)12months:I:31.3%C:17.9% OR 2.09, 95% CI, 1.03,4.27) Brody 2017 [56]RCTLos Angeles, USAMale smokers 10–40 cigarettes/day, outpatients with schizophrenia, expressed desire to obtain smoking cessation treatment and quit smokingNo. randomised: 42I: 14I2:14C:14I: UC + 40 min motivational interviewing based counselling session, specific adaptation tailored for SMI, access to free phone, text based and/or web-based counselling by Quitline service provider incl. 5 proactive calls, unlimited inbound call, 4 weeks free transdermal NRT patchesC: usual hospital care. Brief SC information, self help materials, offer of NRTCBT delivered by experienced psychologist• BV 7 day PPA at 26 weeks (CO)• Cigarettes per day• Exhaled CO level• Fagerstrom Test for Nicotine DependencePPA at 26 weeks:I1:20%I2 (+ home visits): 45%C:8%sig. between I2 and C: (p = 0.03)(But not betweenI1 & C: p = 0.4) or I2 &I1: (p = 0.2)Cigarettes per dayWeek 0Week 12Week 26I18.5 (7.5)3.5 (4.1)4.5 (4.2)I218.6 (9.2)4.5 (6.1)2.5 (3.6)C19.6 (8.5)10.0 (9.7)12.2 (12.1)Exhaled CO levelWeek 0Week 12Week 26I12.3 (9.9)5.6 (4.0)5.0 (3.3)I212.0 (4.8)5.9 (4.5)5.0 (4.4)C11.5 (5.1)7.8 (7.9)10.7 (7.6)Fagerstom test for nicotine dependenceWeek 0Week 12Week 26I5.9 (1.6)3.5 (2.1)2.9 (2.4)I26.2 (2.1)2.8 (2.5)2.0 (2.0)C6.5 (2.5)4.1 (2.4)4.3 (2.6) Brown 2021 [57]RCTUSAInpatients at a psychiatric hospital with serious mental illness who smoked > 5 cigarettes/day when not an inpatient, Austin, TexasTotal sample: 353I:174C: 179I: Sustained Care – inpatient motivational counselling; free nicotine patches at discharge; offer of post-discharge quitline/text/web counselling; automated post-discharge IVR/text follow-ups.C: Usual Care (UC) – nurse-delivered brief advice, self-help materials, and offer of inpatient NRTHospital based MSc level social workers (followed written protocol)• BV 7-day PPA @6 months• Self-reported treatment usage: counselling & pharmacotherapy use at 1, 3, and 6 months6-month PPAI: 15(8.9%)C: UC 6(3.5%) aOR (2.95, 95% CI 1.24,6.99)Use of SC treatment after hospital discharge:Any SC treatment use @1 month:I:102/169 60.4%C:35/173 20.2%(RR 2.98, 95% 2.17,4.11)@3 months (cumulative):I:118 69.8%C:57 (32.9%)(RR 2.12, 95% CI 1.68,2.68)@6 months (cumulative)I: 126 (74.6)C: 70 (40.5)RR 1.84 (95% CI 1.51,2.25)SC counselling use @1 month:I: 36 (21.3%)C: 8 (4.6%)RR 4.61, (95% CI 2.02,9.69)@3 months (cumulative):I: 53 (31.4%)C:16 (9.2%)RR 3.39, (95% CI 2.13, 5.42)@6 months (cumulative)I: 63 (37.3)C:19 (11.0%)RR 3.39, 95%CI 2.13,5.42SC medication use @1 month:I: 99 (58.6%)C: 31 (17.9%)RR 3.27 (95% CI 2.32, 4.61)@3months (cumulative):I: 112 (66.3%)C: 52 (30.0%)RR 2.20 95% CI 1.71,2.84)@6months (cumulative):I: 120 (71.0%)C: 64 (37.0)RR 1.92, 95% CI 1.54,2.38) Brunette 2018 [48]Pilot RCTUSA (New Hampshire, New York, Illinois, USAStable outpatients aged 18–30yrs in with schizophrenia-spectrum, bipolar, or severe mood/anxiety disorders and daily smoking, Intention to quit NOT requiredNo randomised: 89I: 30I2:28C: 23I: “Let’s Talk About Smoking” single-session (30–90 min) interactive multimedia motivational decision support web tool with personalised feedback, videos of peers, pros/cons exercises and treatment referral.I2: Computerised National Cancer Institute Patient Education – similar-length static computerised version of National Cancer Unit leaflet.Quasi-experimental control group: No intervention.Computed based intervention• BV 7-day PPA (CO < 9ppm) at 14 weeks.• Self-reported use of SC treatment• Self-reported quit attempts• Fagerstrom test for nicotine dependence• Stage of Change questionBV 7-day PPA @ 14 weeks:I:2I2: 0 (14.8%) X2 =3.7 (p = 0.05)C: 0Self-reported use of treatment:Met with doctor to discuss cessation:I: 2/27 (7.4%)C:1/23 (4.3%)Attended SC counselling:I:2/27 (7.4%)C:2/23 (8.7%)Initiated SC medication:I: 0/27C: 0/23Initiated NRT:I: 3/27 (11.1%)C: 5/23 (21.7%)Talked to a friend about quitting:I: 5/27 (18.5%)C:6/23 (26.1%) Christiansen 2018 [55]RCTWisconsin, USA.People receiving outpatient mental health services smokers with severe mental illness and who smoke but not motivated to quit in next 30 days;Total randomised: 222I:118C: 104I: x4 motivational sessions with peer researcher + NRTC: x4 20–30 min sessions with peer researcher reviewing booklets about effects of smoking. Support to phone Wisconsin telephone quit line and if set a quit date optional 4 more weekly motivational and behavioural sessionsDelivered by Peer specialists/researcher/research assistant – state certified individuals in recovery from mental illness who have received training to support the recovery of others with mental illness by sharing lived experience.• BV PPA @ 3months• Self-reported abstinence• Stage of change• Engagement in cessation treatment post-intervention (e.g., further counselling, Quitline, meds).• Self-reported quit attempts• Self-reported readiness to prepare to quit.PPA @3 months (dropouts ignored):I: 8.5%C: 1.0% (p = 0.05)PPA @3months (Dropouts assumed to be missing):I: 8.5%C: 1.0% (p = 0.01)At end of treatment:Cigarettes per day I: 12.6, C: 18.6 (P < 0.001)Readiness to quit I: 5.4, C:4.0 (p < 0.001)Confidence in quitting I: 5.6, C:4.5 (p = 0.017)Willingness to set a quit date in next 30 days I: 34.3%, C: 13.8% (p = 0.002)Stage of change:Precontemplation I: -39.2% C: 55.0%Preparation I:-30.4% C: 13.8% p = 0.029) Daumit 2023 [66]RCTMaryland, USAAdults with serious mental illness (schizophrenia-spectrum, bipolar, major depression) attending community mental-health programs and smoking daily, willingness to attempt smoking cessation within 6 monthsTotal randomised = 192I: 97C: 95(Stratified by readiness to quit within 1 month vs. 6 months)Encouraged initiation of Varenicline or NRT2 options:Option 1: 7 weeks behavioural SC for those ready to quit in 1 monthOption 2: 4 weeks of motivational enhancement for those not ready to quitC: Referral to phone smoking quitline offering free NRT. List of exercise resources, quarterly health newsletter and ‘aim for a health weight’ informational guide.Delivered by study health coaches who were bachelor and MSc level research staff.• BV 7 day PPA @18months (CO <8ppm)• Abstinence at 6,12,15 and 18 months• Continuous smoking abstinence from 15-18months (defined as PPA @15 and 18 months)PPA @18 months:I: 26.5%C:5.7%(Adjusted OR 5.9, 95% CI 2.3,15.4; P < 0.001)PPA @ 6months:I:12.2%C:2.8% (AOR 4.8, 95% CI 1.3,17.5)PPA at 12 monthsI: 17.2C: 1.9%(AOR 10.8, 95% CI 2.4, 48.6)PPA @ 15 monthsI:20.2%C: 5.7%(AOR 4.2, 95% CI 1.6,10.9)Continuous abstinence 15–18 months:AOR 3.9 (95% CI 1.2,12.3) Hall 2006 [70]RCTUSAMental outpatient clinics - people with diagnosis unipolar depression, smoking > 1 cigarette/dayNo. Randomised: 322I: 163C:159I: Computerised motivational feedback with counsellor support followed by SC treatment programme for pts who had reached contemplation stage based on computerised feedback reports. 6 x SC sessions, NRT patchesC: Brief visit with folder containing a list of referrals to SC programmes and stop smoking guide.Counsellors with (MSc or clinical psychologist)• BV PPA (CO < 10PPM) @ at 3,6, 12 and 18 months• Any self reported quit attempt• Fagerstrom Test for Dependence• Thoughts about AbstinenceAbstinence rates @ Month 3I: 15.95%C: 11.63%@ 6 MonthsI: 18.4% of 125C:20.83% of 120@ 12 MonthsI: 13.39% of 113C:20.35% of 112@18 MonthsI: 19.09% of 122C: 24.59% of 110Self-reported quit attempts (by No. cigarettes smoked at baseline and treatment condition:@ 3 months> 20 cigarettes at baseline (intervention) 44.8%< 20 cigarettes at baseline (intervention) 60.2%> 20 cigarettes at baseline (control) 24.2%< 20 cigarettes at baseline (control) 57.9%@6 months> 20 cigarettes at baseline (I) 58.3%< 20 cigarettes at baseline (I) 51.1%> 20 cigarettes at baseline (control) 29.0%< 20 cigarettes at baseline (control) 67.1%@12 months> 20 cigarettes at baseline (I) 50.0%< 20 cigarettes at baseline (I) 61.8%> 20 cigarettes at baseline (control) 26.7%< 20 cigarettes at baseline (control) 64.6%@18 months> 20 cigarettes at baseline (I) 47.4%< 20 cigarettes at baseline (I) 55.4%> 20 cigarettes at baseline (control) 37.5%< 20 cigarettes at baseline (control) 52% Gilbody 2019 [27]Pragmatic RCTUK16 primary care & 21 community Mental health sites; people with serious mental illness schizophrenia/bipolar smoking ≥ 5 cigarettes/day, interest in cutting down or quitting smokingNo. randomised: 526I: 265C: 261I: Bespoke SMI cessation service – 8–12 tailored sessions by trained MH smoking practitioners plus pharmacotherapy (incl NRT) through primary care; adaptations: extended pre-quit sessions (focussed on reduction to quit), home visits, post-quit follow-up.C: Usual Care – brief advice + referral to standard smoking services (not tailored) including access to SC counsellor, behavioural support and pharmacotherapy.Delivered by trained mental health smoking cessation practitioners The smoking cessation practitioners were experienced mental health nurses who worked in conjunction with the participant or mental health specialist to provide individually tailored SC service.• BV 7-day PPA @ 6 and 12 months (CO < 10ppm)• No of cigarettes smoked• Prescriptions of NRT treatment and SC products• Fagerstrom test for Nicotine DependenceMotivationBV PPA @ 12 monthsI:34 (15%)/223C: 22 (10%)/219Risk difference 7.7% 95% CI 2.1%, 13.3%)Unadjusted 1.6 (95% CI 0.9,2.9 p = 0.10)AOR 1.6 (95% CI 0.9,2.8 p = 0.12)BV PPA @ 6 months:I:32/226 (14%)C: 14/217(6%)Risk difference 7.7% 95% CI 2.1%, 13.3%)No. cigarettes smoked:6 months:I: 17.7 (95% CI 15.8,19.5)C: 18.0 (95% CI 16.5, 19.4)IRR 0.90 (0.80,1.01) P = 0.07912 monthsI: 19.7 (95% CI 17.8,21.7)C: 18.7 (95% CI 16.9, 20.4)IRR 1.00 (95% CI 0.89,1.13)Fagerstrom test for nicotine dependence:6 months:I: 5.25 (95% CI 5.0,5.50)C: 5.43 (95% CI, 5.19,5.67)IRR: − 0.18 (95% CI -0.53,0.17)12 months:I: 5.42 (95% CI 5.14, 5.70)C: 5.43 (95% CI 5.16,5.69)IRR: -0.01 (95% CI -0.39,0.38)Motivation to quit6 months:I: 13.1 (95% CI 12.6, 13.5)C: 12.5 (95% CI 12.0,12.9)IRR: 0.58 (95% CI -0.01,1.17)12months:I: 12.9 (95% CI 12.4,13.4)C: 12.3 (95% CI 11.8,12.7)IRR: 0.64 (95% CI 0.04,1.24) MacPherson 2010 [52]RCTMaryland, USAPeople 18-65yrs, smoking > 10 cigarettes/day, Beck Depression score > 10 but not diagnosis of major depressive disorderNo Randomised: 68I: 35C:33I: NRT, Behavioural activation therapy 30 min + 30 min ST componentsC: 8 × 1 h weekly group sessions (covering self-monitoring, identifying effective/ineffective cessation strategies, relaxation, coping with triggers, identifying social support for cessation, making lifestyle changes, relapse prevention and homework, NRTTherapists (2 clinical psychologists, three were clinical psychology doctoral students)BV 7-day PPA at 1,4,16 and 26 weeks (CO and cotinine)Continuous abstinence (length of time from quit day until the end of follow-up period)•BV 7-day PPA at 1 week:I: 28.6%C:9.1% (OR 4.0)At 4 weeks:I: 17.1%C:9.1% (OR 2.06)At 16 weeks:I: 11.4%C3.0% (OR 2.71)At 26 weeks:I: 14.3%C: 0.0% (OR -)Generalised Estimation Equations Analyses across all time points: OR 3.59 (95% CI 1.22, 10.53) Metse 2017 [59]RCTNew South Wales, AustraliaAdults admitted to four psychiatric inpatient facilities, smoked any number of cigarettes in the month prior to hospital admissionNo randomised: 754I:379C:375I: whilst an inpatient: motivational interview, self help material.At discharge: NRT (patches, inhalator, gum and lozenges) + 4 months tailored telephone behavioural smoking counselling support and 12 weeks free NRT. Encouraged to use Quitline and were referred if consented.C: Routine hospital smoking cessation care incl. assessment of smoking status and nicotine dependence on admission, brief advice to quit, NRT whilst an inpatient and up to 3 days on discharge, referral to NSW QuitlineSC telephone counsellor• BV PPA (CO <7ppm) at 6 and 12 months• 1 month prolonged smoking abstinence• Number of cigarettes smoked per day• Reduction in cigarettes relative to baseline• Quit attempts• Fagerstrom Test for Nicotine dependence• Readiness to quit.7 day PPA at 6 months post dischargeI: (59/373) 15.8%C: (34/367) 9.3%OR (1.07, 95% CI 1.01,1.14)7 day at 12 months:I: 50/373 13.4%C: 37/367 10.0%OR (1.03, 95% CI 0.98, 1.09)Prolonged abstinence (greater than 1 month) at 6 months:I: 45/373 (45%)C: 35/367 (35%)OR 1.02 (95% CI, 0.96, 1.08)Prolonged abstinence (greater than 1 month) at 12 months:I: 44/373 (11.8%)C: 37/367 (10.1%)OR: 1.01 (95% CI, 0.96,1.07)50% Reduction in cigarettes at 6 monthsI: 217/373 (58.2%)C: 135/367 (36.8%)OR 1.24 (95% CI 1.13,1.36)50% Reduction in cigarettes at 12 monthsI: 201/373 (53.9%)C:162/367 (44.1%)OR: 1.10 (95% CI 1.0,1.21)Quit attempts at 12 months:I: 189/373 (50.7%)C: 110/367 (30.0%)OR: 1.23, 95% CI 1.12, 1.35Quit attempts at 6 months:I: 139/373 (37.3%)C: 83/367 (21.6%)OR: 1.17, (95% CI 1.07, 1.28)Fagerstom test for dependence 6 months:I: 266/373 (71.3%)C:232/367 (63.2%)OR: 1.09 (95% CI 1.0, 1.18)Fagerstrom test for dependence at 12 months:I:244/373 (65.4%)C: 224/367 (61.0%)OR: 1.04, (95% CI 0.96,1.14)Readiness to quit at 6 months:I: 200/373 (53.6%)C: 173/367 (47.1%)OR: 1.07, 95% CI 0.97, 1.17)Readiness to quit at 12 months:I: 197/373 (52.8%)C: 191/367 (52.0%)OR: 1.01 (95% CI 0.92,1.11) Minami 2022 [51]RCTBronx, New York, USAOutpatient community behavioural centre, receiving treatment for depression or bipolar smoking > 5 cigarettes/day, intention to quit within 3 monthsNo randomised: 49I: 25C:24I: Contingency management, individual counselling sessions, smartphone based intervention, 8 weeks NRT, randomly scheduled prompts for mindfulness, CO monitor with monetary incentives for verified CO quit.C: SC counselling as in intervention group, non-contingent incentives via app, NRT patchesUnclear who delivered the counselling sessionsBV 7 days PPA at 2 weeks, 4 weeks and 3 monthsChanges in No. cigarettes smokedBV PPA at 2 weeks:I: 40%C: 4.2%BV PPA at 4 weeks:I: 36%C:8.3%BV PPA at 3 months:I: 16%C: 4.2%GEE model for abstinence (across all time points):AOR 8.12, 95% CI 1.42, 46.6) p = 0.019Reduction in No. cigarettes smoked:Week 2:I: 79.4%C:64.4%Week 4:I: 79.9%C:62.9%Week 12:I: 61.4%C:47.9%GEE model:Non sig. reduction in intervention vs. control (b= -1.54, 95% CI -3.34, 0.27) p = 0.096) Patten 2017 [47]Pilot RCTMinnesota, USAWomen smoking > 10 cigarettes day, willing to make quit attempt, > 16 CESD ScaleNo. randomised: 30I: 15C: 15I: 12 weeks of in-person exercise sessions (3 sessions per week) including, warm-up, 20–30 min of aerobic exercise, and cool-down, Exercise intensity increased over time, targeting vigorous levels. Smoking cessation counselling for 20–30 min at one session each week. At week 2 and 6, a 4 week supply of NRT patches.C: Same as intervention except the use of exercise was not discussed as a strategy for managing depression, craving or withdrawal symptomsSC counselling delivered by health education or exercise wellness coachBV PPA at week 12 and 6 months (cotinine verification)NRT AdherenceWeek 12 7 day BV PPAI: 11/15 73%C: 5/15 33%P = 0.0286 month 7 day PPA:I: 4/15 (27%)C: 6/16 (40%)P = 0.439NRT adherence (completed 8 weeks of nicotine patches):I: 4/15 27%C:2/15 27% Prochaska 2014 [62]RCTCalifornia, USAInpatients at psychiatric hospital, smoking > 5 cigarettes/day.No Randomised: 224I: 113C: 111I: During hospitalisation, received motivationally tailored counselling + NRTPost-discharge, offered 10 weeks NRT + proactive phone and in-person cessation support.Control: ‘usual inpatient psychiatric care’ (not described)Inpatient counselling session delivered by ‘study counsellor’ unclearBV 7-day PPA at 3, 6, 12, and 18 months.Fagerstrom test for nicotine dependence,Thoughts about abstinence scaleBehaviour and symptom identification scaleGEE comparing the verified 7-day PPA across the postbaseline assessments with7 day PPA at 3 months:I:13.9%C:3.2%7 day PPA at 6 monthsI: 14.4%C:6.5%7 day PPA at 12 monthsI:19.4%C:10.9%7 day PPA at 18 monthsI:20.0%C:7.7%Overall GEE model (adjustment for stage of change (related to attrition).OR 3.15 (95% CI 1.22, 8.14] P = 0.018 Rogers 2018 [49]RCTNew York, Minneapolis, Texas, Florida, USAAdults > 18yrs who smoked within the last 30 days and using a Veterans Administration mental health facility in past 12 monthsTotal randomised: 1,938I: 969C: 969I: Proactive outreach by telephone: Enrollment in telephone-based tobacco treatment rather than waiting for them to seek help). Access to smoking cessation medications, Counselling delivered through a state tobacco Quitline + NRT.C: Usual care available through VA mental health clinic: SC advice only if initiated by the patient or provider.Study counsellors MSc in counselling fieldBV PPA at 6 and 12 months (assays of cotinine)Treatment useBV PPA at 6 months:I: 146/726 20.1%C: 94/776 12.1%(OR 1.82 95% CI 1.37,2.41)BV PPA a 12 months:I: 119/620 19%C: 96/701 13.7%(OR 1.5, 95% CI 1.1, 2.0)At 12 monthstelephone counselling use:I: 19%C: 3% (OR 7.34, 95% CI 4.59,11.74)Use of NRT:I: 47%C:35% (OR 1.63, 95% CI 1.31, 2.03)Counselling and NRT:I: 16%C:2% (OR 11.93, 95% CI 6.34,22.47) Stockings 2014 [61]RCTNew South Wales, AustraliaAdults > 18yrs inpatients at psychiatric hospital (imposed smoking ban), self-reported current or occasional smoker, fluency in EnglishTotal randomised: 205I: 104C: 101I: treatment as usual + self-help SC information, 15 min motivational interview, 2 week supply of NRT, 4 months 2 weekly telephone SC support who offered 12-week additional supply of tailored NRT, referral to Quitline ad referral to community run SC groupsC: Nicotine dependence treatment provided by hospital admitted and on discharge including: assessment of smoking status, brief advice to quit, provision of NRT during admission and 3 days upon discharge and post discharge smoking care planDelivered by project officer for motivational interview, designated SC counsellor for ongoing supportBV 7 day PPA (CO < 10 ppm)Quit attempts50% reduction in cigarettes per day7-day PPA at:1 week:I: 7/104 6.7%C: 5/101 5.0% (OR 1.37, 95% CI 0.45, 4.98) NSS2 months:I: 11/104 10.6%C: 5/101 5.0%OR 2.27 95% CI 0.81, 7.52)4 month:I: 11.5%C:2.0%OR 6.46 (95% CI 1.50,32.77)6 months:I:8/104 7.7%C:6/101 5.9%OR 1.32, 95% CI 0.47,4.36)Continuous abstinence at 1 week, 2 week, 4 months, 6months:I: 1%, 0%, 0%, 0%C: 5.8%, 2.9%, 1.9%,1.9% (not SS)Quit attempts:2 months:I: 50/104 48%C:28/101 27.7% (OR 2.41, 95% CI 1.35, 4.44)4 months:I: 48/104 46.2%C:25/101 24.8%OR 2.61, 95% CI 1.44, 4.85)6 months:I: 33/104 31.7%C:14/101 13.9%OR 2.89, 95% CI 1.43, 5.98) 50% reduction in cigarettes per day1 week:I: 27/104 26%C:10/101 9.9%OR 3.19, (95% CI, 1.57, 8.18)2 months:I: 31/104C:13/101OR 2.88, (95% CI 1.51, 6.88)4 months:I: 35/104 33.7%C: 9/101 8.9%OR 5.19 (95% CI 2.53, 13.47)6 months:I: 38/104 36.5%C:9/101 8.9%OR 5.90 (95% CI 2.89, 15.25) Taylor 2025 [46]Randomised feasibility trialUKAdults > 18yrs, receiving standard improving access to psychological therapies’ IAPT psychological care for their depression and anxiety symptoms/diagnosis, smoking daily for > 1 year, interested in receiving help to quit smokingTotal randomised: 135I: 68C:67I: Training IAPT practitioners to deliver SC support as detailed in NCSCT standard behavioural treatment. Psychoeducation using a co-designed CBT framework to outline tobacco withdrawal cycle worsening mental wellbeing + NRTC: Usual care + signposting to local smoking cessation service during last IAPT appt.IAPT practitioners (Counsellors)BV 7 day PPA, (exhaled carbon monoxide concentration < 10 PPM, or cotinine < 10 ng/ml of saliva) at 3 months and 6 monthsQuit attemptsHeaviness of smoking indexMean cigarettes smoked per dayBV PPA at 3 months:I: 8/68 11.8%C:1/67 1.5%OR 8.69 (95% CI 1.11,396.26)Quit attempt at 3 monthsI: 14/69 (20.6%)C: 4/67 (6.0%)OR 4.04, 95% CI 1.18, 17.88)Heaviness of smoking index at 3 months:I: mean 2.0 (SD 1.7)C: mean 2.0 (1.5)B coefficient: -0.17, 95% CI -0.94,0.60)Cigarettes per day (CPD) at 3 months:I: mean 9.5 (SD 8.6)C: mean 9.4 (SD 7.0)B coefficient − 1.09, 95% CI -5.38, 3.20)BC PPA at 6 months:I: 10/68 14.7%C: 4/67 6.0%OR 2.70 (95% CI 0.73,12.43)Quit attempt at 6 months:I: 16/68 (23.5%)C: 9/67 (13.4%)OR 1.97, 95% CI 0.75, 5.53)Mean HSI at 6 months:I: 2.2 (SD 1.9)C: 2.0 (SD 1.7)B coefficient − 0.12 (95% CI, -0.81, 0.57)Mean CPD at 6 months:I: 10.9 (9.6)C: 9.9 (8.5)B Coefficient − 1.64, 95% CI -5.11, 1.83) Characteristics of included studies RCT Syndey and Newcastle, Australia. Smokers > 18yrs, smoking > 15 cigarettes/day with non-acute psychotic disorder residing in the community with interest in quitting smoking Total: 298 I:147 C: 151 I: x8 individual 1-hour sessions of motivational interviewing and CBT + NRT +treatment as usual and booklet on SC C: Treatment as usual: booklets on SC, access to GPs and publicly funded mental health teams. Therapy delivered by trained therapist • Biochemically verified (BV) Point prevalence abstinence (PPA)* @ 3, 6 and 12 months • Continuous abstinence (3,6 and 12months) • Smoking reduction (reduction of daily consumption of cigarettes by 50% or greater (incl. abstinence) relative to baseline • Fagerstrom Test for Nicotine Dependence • Motivation to Quit smoking PPA @ 3 months: I:15% C:6% (OR 2.78 99% CI 1.78,24.41) PPA @ 6 months: I:9.5% C: 4.0% OR2.54 (99% CI 0.70,9.28) PPA @ 12 months: I:10.9%, C: 6.6% 1.72 (99% CI 0.58, 5.09) Continuous abstinence @3 months I: 10.9% C:4% OR 2.95, 95% CI, 0.83,10.53) CA @6 months: I: 5.4 C:2.0 OR 2.84 (95% CI 0.48,16.67) CA at 12months: I: 0.7 C: 3.4 (OR 5.28 (95% CI 0.31, 90.20) Smoking reduction of 50% or > relative to baseline: 3 months: I:43.5% C:16.6% (OR 3.89, 95% CI 1.91,7.89) 6 months: I:29.9% C:18.5% (OR 1.88, 95% CI 0.92,3.82) 12months: I:31.3% C:17.9% OR 2.09, 95% CI, 1.03,4.27) RCT Los Angeles, USA Male smokers 10–40 cigarettes/day, outpatients with schizophrenia, expressed desire to obtain smoking cessation treatment and quit smoking No. randomised: 42 I: 14 I2:14 C:14 I: UC + 40 min motivational interviewing based counselling session, specific adaptation tailored for SMI, access to free phone, text based and/or web-based counselling by Quitline service provider incl. 5 proactive calls, unlimited inbound call, 4 weeks free transdermal NRT patches C: usual hospital care. Brief SC information, self help materials, offer of NRT CBT delivered by experienced psychologist • BV 7 day PPA at 26 weeks (CO) • Cigarettes per day • Exhaled CO level • Fagerstrom Test for Nicotine Dependence PPA at 26 weeks: I1:20% I2 (+ home visits): 45% C:8% sig. between I2 and C: (p = 0.03) (But not between I1 & C: p = 0.4) or I2 &I1: (p = 0.2) Cigarettes per day RCT USA Inpatients at a psychiatric hospital with serious mental illness who smoked > 5 cigarettes/day when not an inpatient, Austin, Texas Total sample: 353 I:174 C: 179 I: Sustained Care – inpatient motivational counselling; free nicotine patches at discharge; offer of post-discharge quitline/text/web counselling; automated post-discharge IVR/text follow-ups. C: Usual Care (UC) – nurse-delivered brief advice, self-help materials, and offer of inpatient NRT Hospital based MSc level social workers (followed written protocol) • BV 7-day PPA @6 months • Self-reported treatment usage: counselling & pharmacotherapy use at 1, 3, and 6 months 6-month PPA I: 15(8.9%) C: UC 6(3.5%) aOR (2.95, 95% CI 1.24,6.99) Use of SC treatment after hospital discharge: Any SC treatment use @1 month: I:102/169 60.4% C:35/173 20.2% (RR 2.98, 95% 2.17,4.11) @3 months (cumulative): I:118 69.8% C:57 (32.9%) (RR 2.12, 95% CI 1.68,2.68) @6 months (cumulative) I: 126 (74.6) C: 70 (40.5) RR 1.84 (95% CI 1.51,2.25) SC counselling use @1 month: I: 36 (21.3%) C: 8 (4.6%) RR 4.61, (95% CI 2.02,9.69) @3 months (cumulative): I: 53 (31.4%) C:16 (9.2%) RR 3.39, (95% CI 2.13, 5.42) @6 months (cumulative) I: 63 (37.3) C:19 (11.0%) RR 3.39, 95%CI 2.13,5.42 SC medication use @1 month: I: 99 (58.6%) C: 31 (17.9%) RR 3.27 (95% CI 2.32, 4.61) @3months (cumulative): I: 112 (66.3%) C: 52 (30.0%) RR 2.20 95% CI 1.71,2.84) @6months (cumulative): I: 120 (71.0%) C: 64 (37.0) RR 1.92, 95% CI 1.54,2.38) Pilot RCT USA (New Hampshire, New York, Illinois, USA Stable outpatients aged 18–30yrs in with schizophrenia-spectrum, bipolar, or severe mood/anxiety disorders and daily smoking, Intention to quit NOT required No randomised: 89 I: 30 I2:28 C: 23 I: “Let’s Talk About Smoking” single-session (30–90 min) interactive multimedia motivational decision support web tool with personalised feedback, videos of peers, pros/cons exercises and treatment referral. I2: Computerised National Cancer Institute Patient Education – similar-length static computerised version of National Cancer Unit leaflet. Quasi-experimental control group: No intervention. Computed based intervention • BV 7-day PPA (CO < 9ppm) at 14 weeks. • Self-reported use of SC treatment • Self-reported quit attempts • Fagerstrom test for nicotine dependence • Stage of Change question BV 7-day PPA @ 14 weeks: I:2 I2: 0 (14.8%) X2 =3.7 (p = 0.05) C: 0 Self-reported use of treatment: Met with doctor to discuss cessation: I: 2/27 (7.4%) C:1/23 (4.3%) Attended SC counselling: I:2/27 (7.4%) C:2/23 (8.7%) Initiated SC medication: I: 0/27 C: 0/23 Initiated NRT: I: 3/27 (11.1%) C: 5/23 (21.7%) Talked to a friend about quitting: I: 5/27 (18.5%) C:6/23 (26.1%) RCT Wisconsin, USA. People receiving outpatient mental health services smokers with severe mental illness and who smoke but not motivated to quit in next 30 days; Total randomised: 222 I:118 C: 104 I: x4 motivational sessions with peer researcher + NRT C: x4 20–30 min sessions with peer researcher reviewing booklets about effects of smoking. Support to phone Wisconsin telephone quit line and if set a quit date optional 4 more weekly motivational and behavioural sessions Delivered by Peer specialists/researcher/research assistant – state certified individuals in recovery from mental illness who have received training to support the recovery of others with mental illness by sharing lived experience. • BV PPA @ 3months • Self-reported abstinence • Stage of change • Engagement in cessation treatment post-intervention (e.g., further counselling, Quitline, meds). • Self-reported quit attempts • Self-reported readiness to prepare to quit. PPA @3 months (dropouts ignored): I: 8.5% C: 1.0% (p = 0.05) PPA @3months (Dropouts assumed to be missing): I: 8.5% C: 1.0% (p = 0.01) At end of treatment: Cigarettes per day I: 12.6, C: 18.6 (P < 0.001) Readiness to quit I: 5.4, C:4.0 (p < 0.001) Confidence in quitting I: 5.6, C:4.5 (p = 0.017) Willingness to set a quit date in next 30 days I: 34.3%, C: 13.8% (p = 0.002) Stage of change: Precontemplation I: -39.2% C: 55.0% Preparation I:-30.4% C: 13.8% p = 0.029) RCT Maryland, USA Adults with serious mental illness (schizophrenia-spectrum, bipolar, major depression) attending community mental-health programs and smoking daily, willingness to attempt smoking cessation within 6 months Total randomised = 192 I: 97 C: 95 (Stratified by readiness to quit within 1 month vs. 6 months) Encouraged initiation of Varenicline or NRT 2 options: Option 1: 7 weeks behavioural SC for those ready to quit in 1 month Option 2: 4 weeks of motivational enhancement for those not ready to quit C: Referral to phone smoking quitline offering free NRT. List of exercise resources, quarterly health newsletter and ‘aim for a health weight’ informational guide. Delivered by study health coaches who were bachelor and MSc level research staff. • BV 7 day PPA @18months (CO <8ppm) • Abstinence at 6,12,15 and 18 months • Continuous smoking abstinence from 15-18months (defined as PPA @15 and 18 months) PPA @18 months: I: 26.5% C:5.7% (Adjusted OR 5.9, 95% CI 2.3,15.4; P < 0.001) PPA @ 6months: I:12.2% C:2.8% (AOR 4.8, 95% CI 1.3,17.5) PPA at 12 months I: 17.2 C: 1.9% (AOR 10.8, 95% CI 2.4, 48.6) PPA @ 15 months I:20.2% C: 5.7% (AOR 4.2, 95% CI 1.6,10.9) Continuous abstinence 15–18 months: AOR 3.9 (95% CI 1.2,12.3) RCT USA Mental outpatient clinics - people with diagnosis unipolar depression, smoking > 1 cigarette/day No. Randomised: 322 I: 163 C:159 I: Computerised motivational feedback with counsellor support followed by SC treatment programme for pts who had reached contemplation stage based on computerised feedback reports. 6 x SC sessions, NRT patches C: Brief visit with folder containing a list of referrals to SC programmes and stop smoking guide. Counsellors with (MSc or clinical psychologist) • BV PPA (CO < 10PPM) @ at 3,6, 12 and 18 months • Any self reported quit attempt • Fagerstrom Test for Dependence • Thoughts about Abstinence Abstinence rates @ Month 3 I: 15.95% C: 11.63% @ 6 Months I: 18.4% of 125 C:20.83% of 120 @ 12 Months I: 13.39% of 113 C:20.35% of 112 @18 Months I: 19.09% of 122 C: 24.59% of 110 Self-reported quit attempts (by No. cigarettes smoked at baseline and treatment condition: @ 3 months > 20 cigarettes at baseline (intervention) 44.8% < 20 cigarettes at baseline (intervention) 60.2% > 20 cigarettes at baseline (control) 24.2% < 20 cigarettes at baseline (control) 57.9% @6 months > 20 cigarettes at baseline (I) 58.3% < 20 cigarettes at baseline (I) 51.1% > 20 cigarettes at baseline (control) 29.0% < 20 cigarettes at baseline (control) 67.1% @12 months > 20 cigarettes at baseline (I) 50.0% < 20 cigarettes at baseline (I) 61.8% > 20 cigarettes at baseline (control) 26.7% < 20 cigarettes at baseline (control) 64.6% @18 months > 20 cigarettes at baseline (I) 47.4% < 20 cigarettes at baseline (I) 55.4% > 20 cigarettes at baseline (control) 37.5% < 20 cigarettes at baseline (control) 52% Pragmatic RCT UK 16 primary care & 21 community Mental health sites; people with serious mental illness schizophrenia/bipolar smoking ≥ 5 cigarettes/day, interest in cutting down or quitting smoking No. randomised: 526 I: 265 C: 261 I: Bespoke SMI cessation service – 8–12 tailored sessions by trained MH smoking practitioners plus pharmacotherapy (incl NRT) through primary care; adaptations: extended pre-quit sessions (focussed on reduction to quit), home visits, post-quit follow-up. C: Usual Care – brief advice + referral to standard smoking services (not tailored) including access to SC counsellor, behavioural support and pharmacotherapy. Delivered by trained mental health smoking cessation practitioners The smoking cessation practitioners were experienced mental health nurses who worked in conjunction with the participant or mental health specialist to provide individually tailored SC service. • BV 7-day PPA @ 6 and 12 months (CO < 10ppm) • No of cigarettes smoked • Prescriptions of NRT treatment and SC products • Fagerstrom test for Nicotine Dependence Motivation BV PPA @ 12 months I:34 (15%)/223 C: 22 (10%)/219 Risk difference 7.7% 95% CI 2.1%, 13.3%) Unadjusted 1.6 (95% CI 0.9,2.9 p = 0.10) AOR 1.6 (95% CI 0.9,2.8 p = 0.12) BV PPA @ 6 months: I:32/226 (14%) C: 14/217(6%) Risk difference 7.7% 95% CI 2.1%, 13.3%) No. cigarettes smoked: 6 months: I: 17.7 (95% CI 15.8,19.5) C: 18.0 (95% CI 16.5, 19.4) IRR 0.90 (0.80,1.01) P = 0.079 12 months I: 19.7 (95% CI 17.8,21.7) C: 18.7 (95% CI 16.9, 20.4) IRR 1.00 (95% CI 0.89,1.13) Fagerstrom test for nicotine dependence: 6 months: I: 5.25 (95% CI 5.0,5.50) C: 5.43 (95% CI, 5.19,5.67) IRR: − 0.18 (95% CI -0.53,0.17) 12 months: I: 5.42 (95% CI 5.14, 5.70) C: 5.43 (95% CI 5.16,5.69) IRR: -0.01 (95% CI -0.39,0.38) Motivation to quit 6 months: I: 13.1 (95% CI 12.6, 13.5) C: 12.5 (95% CI 12.0,12.9) IRR: 0.58 (95% CI -0.01,1.17) 12months: I: 12.9 (95% CI 12.4,13.4) C: 12.3 (95% CI 11.8,12.7) IRR: 0.64 (95% CI 0.04,1.24) RCT Maryland, USA People 18-65yrs, smoking > 10 cigarettes/day, Beck Depression score > 10 but not diagnosis of major depressive disorder No Randomised: 68 I: 35 C:33 I: NRT, Behavioural activation therapy 30 min + 30 min ST components C: 8 × 1 h weekly group sessions (covering self-monitoring, identifying effective/ineffective cessation strategies, relaxation, coping with triggers, identifying social support for cessation, making lifestyle changes, relapse prevention and homework, NRT Therapists (2 clinical psychologists, three were clinical psychology doctoral students) BV 7-day PPA at 1,4,16 and 26 weeks (CO and cotinine) Continuous abstinence (length of time from quit day until the end of follow-up period)• BV 7-day PPA at 1 week: I: 28.6% C:9.1% (OR 4.0) At 4 weeks: I: 17.1% C:9.1% (OR 2.06) At 16 weeks: I: 11.4% C3.0% (OR 2.71) At 26 weeks: I: 14.3% C: 0.0% (OR -) Generalised Estimation Equations Analyses across all time points: OR 3.59 (95% CI 1.22, 10.53) RCT New South Wales, Australia Adults admitted to four psychiatric inpatient facilities, smoked any number of cigarettes in the month prior to hospital admission No randomised: 754 I:379 C:375 I: whilst an inpatient: motivational interview, self help material. At discharge: NRT (patches, inhalator, gum and lozenges) + 4 months tailored telephone behavioural smoking counselling support and 12 weeks free NRT. Encouraged to use Quitline and were referred if consented. C: Routine hospital smoking cessation care incl. assessment of smoking status and nicotine dependence on admission, brief advice to quit, NRT whilst an inpatient and up to 3 days on discharge, referral to NSW Quitline SC telephone counsellor • BV PPA (CO <7ppm) at 6 and 12 months • 1 month prolonged smoking abstinence • Number of cigarettes smoked per day • Reduction in cigarettes relative to baseline • Quit attempts • Fagerstrom Test for Nicotine dependence • Readiness to quit. 7 day PPA at 6 months post discharge I: (59/373) 15.8% C: (34/367) 9.3% OR (1.07, 95% CI 1.01,1.14) 7 day at 12 months: I: 50/373 13.4% C: 37/367 10.0% OR (1.03, 95% CI 0.98, 1.09) Prolonged abstinence (greater than 1 month) at 6 months: I: 45/373 (45%) C: 35/367 (35%) OR 1.02 (95% CI, 0.96, 1.08) Prolonged abstinence (greater than 1 month) at 12 months: I: 44/373 (11.8%) C: 37/367 (10.1%) OR: 1.01 (95% CI, 0.96,1.07) 50% Reduction in cigarettes at 6 months I: 217/373 (58.2%) C: 135/367 (36.8%) OR 1.24 (95% CI 1.13,1.36) 50% Reduction in cigarettes at 12 months I: 201/373 (53.9%) C:162/367 (44.1%) OR: 1.10 (95% CI 1.0,1.21) Quit attempts at 12 months: I: 189/373 (50.7%) C: 110/367 (30.0%) OR: 1.23, 95% CI 1.12, 1.35 Quit attempts at 6 months: I: 139/373 (37.3%) C: 83/367 (21.6%) OR: 1.17, (95% CI 1.07, 1.28) Fagerstom test for dependence 6 months: I: 266/373 (71.3%) C:232/367 (63.2%) OR: 1.09 (95% CI 1.0, 1.18) Fagerstrom test for dependence at 12 months: I:244/373 (65.4%) C: 224/367 (61.0%) OR: 1.04, (95% CI 0.96,1.14) Readiness to quit at 6 months: I: 200/373 (53.6%) C: 173/367 (47.1%) OR: 1.07, 95% CI 0.97, 1.17) Readiness to quit at 12 months: I: 197/373 (52.8%) C: 191/367 (52.0%) OR: 1.01 (95% CI 0.92,1.11) RCT Bronx, New York, USA Outpatient community behavioural centre, receiving treatment for depression or bipolar smoking > 5 cigarettes/day, intention to quit within 3 months No randomised: 49 I: 25 C:24 I: Contingency management, individual counselling sessions, smartphone based intervention, 8 weeks NRT, randomly scheduled prompts for mindfulness, CO monitor with monetary incentives for verified CO quit. C: SC counselling as in intervention group, non-contingent incentives via app, NRT patches Unclear who delivered the counselling sessions BV 7 days PPA at 2 weeks, 4 weeks and 3 months Changes in No. cigarettes smoked BV PPA at 2 weeks: I: 40% C: 4.2% BV PPA at 4 weeks: I: 36% C:8.3% BV PPA at 3 months: I: 16% C: 4.2% GEE model for abstinence (across all time points): AOR 8.12, 95% CI 1.42, 46.6) p = 0.019 Reduction in No. cigarettes smoked: Week 2: I: 79.4% C:64.4% Week 4: I: 79.9% C:62.9% Week 12: I: 61.4% C:47.9% GEE model: Non sig. reduction in intervention vs. control (b= -1.54, 95% CI -3.34, 0.27) p = 0.096) Pilot RCT Minnesota, USA Women smoking > 10 cigarettes day, willing to make quit attempt, > 16 CESD Scale No. randomised: 30 I: 15 C: 15 I: 12 weeks of in-person exercise sessions (3 sessions per week) including, warm-up, 20–30 min of aerobic exercise, and cool-down, Exercise intensity increased over time, targeting vigorous levels. Smoking cessation counselling for 20–30 min at one session each week. At week 2 and 6, a 4 week supply of NRT patches. C: Same as intervention except the use of exercise was not discussed as a strategy for managing depression, craving or withdrawal symptoms SC counselling delivered by health education or exercise wellness coach BV PPA at week 12 and 6 months (cotinine verification) NRT Adherence Week 12 7 day BV PPA I: 11/15 73% C: 5/15 33% P = 0.028 6 month 7 day PPA: I: 4/15 (27%) C: 6/16 (40%) P = 0.439 NRT adherence (completed 8 weeks of nicotine patches): I: 4/15 27% C:2/15 27% RCT California, USA Inpatients at psychiatric hospital, smoking > 5 cigarettes/day. No Randomised: 224 I: 113 C: 111 I: During hospitalisation, received motivationally tailored counselling + NRT Post-discharge, offered 10 weeks NRT + proactive phone and in-person cessation support. Control: ‘usual inpatient psychiatric care’ (not described) Inpatient counselling session delivered by ‘study counsellor’ unclear BV 7-day PPA at 3, 6, 12, and 18 months. Fagerstrom test for nicotine dependence, Thoughts about abstinence scale Behaviour and symptom identification scale GEE comparing the verified 7-day PPA across the postbaseline assessments with 7 day PPA at 3 months: I:13.9% C:3.2% 7 day PPA at 6 months I: 14.4% C:6.5% 7 day PPA at 12 months I:19.4% C:10.9% 7 day PPA at 18 months I:20.0% C:7.7% Overall GEE model (adjustment for stage of change (related to attrition). OR 3.15 (95% CI 1.22, 8.14] P = 0.018 RCT New York, Minneapolis, Texas, Florida, USA Adults > 18yrs who smoked within the last 30 days and using a Veterans Administration mental health facility in past 12 months Total randomised: 1,938 I: 969 C: 969 I: Proactive outreach by telephone: Enrollment in telephone-based tobacco treatment rather than waiting for them to seek help). Access to smoking cessation medications, Counselling delivered through a state tobacco Quitline + NRT. C: Usual care available through VA mental health clinic: SC advice only if initiated by the patient or provider. Study counsellors MSc in counselling field BV PPA at 6 and 12 months (assays of cotinine) Treatment use BV PPA at 6 months: I: 146/726 20.1% C: 94/776 12.1% (OR 1.82 95% CI 1.37,2.41) BV PPA a 12 months: I: 119/620 19% C: 96/701 13.7% (OR 1.5, 95% CI 1.1, 2.0) At 12 months telephone counselling use: I: 19% C: 3% (OR 7.34, 95% CI 4.59,11.74) Use of NRT: I: 47% C:35% (OR 1.63, 95% CI 1.31, 2.03) Counselling and NRT: I: 16% C:2% (OR 11.93, 95% CI 6.34,22.47) RCT New South Wales, Australia Adults > 18yrs inpatients at psychiatric hospital (imposed smoking ban), self-reported current or occasional smoker, fluency in English Total randomised: 205 I: 104 C: 101 I: treatment as usual + self-help SC information, 15 min motivational interview, 2 week supply of NRT, 4 months 2 weekly telephone SC support who offered 12-week additional supply of tailored NRT, referral to Quitline ad referral to community run SC groups C: Nicotine dependence treatment provided by hospital admitted and on discharge including: assessment of smoking status, brief advice to quit, provision of NRT during admission and 3 days upon discharge and post discharge smoking care plan Delivered by project officer for motivational interview, designated SC counsellor for ongoing support BV 7 day PPA (CO < 10 ppm) Quit attempts 50% reduction in cigarettes per day 7-day PPA at: 1 week: I: 7/104 6.7% C: 5/101 5.0% (OR 1.37, 95% CI 0.45, 4.98) NSS 2 months: I: 11/104 10.6% C: 5/101 5.0% OR 2.27 95% CI 0.81, 7.52) 4 month: I: 11.5% C:2.0% OR 6.46 (95% CI 1.50,32.77) 6 months: I:8/104 7.7% C:6/101 5.9% OR 1.32, 95% CI 0.47,4.36) Continuous abstinence at 1 week, 2 week, 4 months, 6months: I: 1%, 0%, 0%, 0% C: 5.8%, 2.9%, 1.9%,1.9% (not SS) Quit attempts: 2 months: I: 50/104 48% C:28/101 27.7% (OR 2.41, 95% CI 1.35, 4.44) 4 months: I: 48/104 46.2% C:25/101 24.8% OR 2.61, 95% CI 1.44, 4.85) 6 months: I: 33/104 31.7% C:14/101 13.9% OR 2.89, 95% CI 1.43, 5.98) 50% reduction in cigarettes per day 1 week: I: 27/104 26% C:10/101 9.9% OR 3.19, (95% CI, 1.57, 8.18) 2 months: I: 31/104 C:13/101 OR 2.88, (95% CI 1.51, 6.88) 4 months: I: 35/104 33.7% C: 9/101 8.9% OR 5.19 (95% CI 2.53, 13.47) 6 months: I: 38/104 36.5% C:9/101 8.9% OR 5.90 (95% CI 2.89, 15.25) Randomised feasibility trial UK Adults > 18yrs, receiving standard improving access to psychological therapies’ IAPT psychological care for their depression and anxiety symptoms/diagnosis, smoking daily for > 1 year, interested in receiving help to quit smoking Total randomised: 135 I: 68 C:67 I: Training IAPT practitioners to deliver SC support as detailed in NCSCT standard behavioural treatment. Psychoeducation using a co-designed CBT framework to outline tobacco withdrawal cycle worsening mental wellbeing + NRT C: Usual care + signposting to local smoking cessation service during last IAPT appt. IAPT practitioners (Counsellors) BV 7 day PPA, (exhaled carbon monoxide concentration < 10 PPM, or cotinine < 10 ng/ml of saliva) at 3 months and 6 months Quit attempts Heaviness of smoking index Mean cigarettes smoked per day BV PPA at 3 months: I: 8/68 11.8% C:1/67 1.5% OR 8.69 (95% CI 1.11,396.26) Quit attempt at 3 months I: 14/69 (20.6%) C: 4/67 (6.0%) OR 4.04, 95% CI 1.18, 17.88) Heaviness of smoking index at 3 months: I: mean 2.0 (SD 1.7) C: mean 2.0 (1.5) B coefficient: -0.17, 95% CI -0.94,0.60) Cigarettes per day (CPD) at 3 months: I: mean 9.5 (SD 8.6) C: mean 9.4 (SD 7.0) B coefficient − 1.09, 95% CI -5.38, 3.20) BC PPA at 6 months: I: 10/68 14.7% C: 4/67 6.0% OR 2.70 (95% CI 0.73,12.43) Quit attempt at 6 months: I: 16/68 (23.5%) C: 9/67 (13.4%) OR 1.97, 95% CI 0.75, 5.53) Mean HSI at 6 months: I: 2.2 (SD 1.9) C: 2.0 (SD 1.7) B coefficient − 0.12 (95% CI, -0.81, 0.57) Mean CPD at 6 months: I: 10.9 (9.6) C: 9.9 (8.5) B Coefficient − 1.64, 95% CI -5.11, 1.83) Four studies were conducted within inpatient psychiatric hospitals for people with SMI [57, 59, 61, 62]. All other studies included people accessing mental health treatment within the community. Four studies included only those accessing treatment for depression [52, 53], depression and anxiety [46] and depression or bipolar disorder [51]. The included studies targeted adult participants > 18 years, with smoking levels ranging from occasional use [58] to more than 15 cigarettes per day [60]. Seven studies included individuals regardless of their motivation to quit [49, 57, 61–65], while three required interest in quitting within a defined timeframe [46, 51, 66]. Two studies specifically recruited those who were not motivated to quit as the intervention was designed to improve motivation to quit or engage in smoking cessation treatment [48, 67]. Two studies were gender-specific, recruiting only men [56] or women [47]. All but one primary study interventions included both psychosocial and pharmacological components. Thirteen studies included a prescription of nicotine replacement therapy in addition to a psychosocial intervention [46, 47, 49, 51, 56, 57, 60–64, 67, 68]. Two studies also offered other pharmacological treatment including varenicline and bupropion in addition to a psychosocial intervention [66, 69]. Only one study did not include a pharmacological element as the focus of the intervention was to increase levels of motivation to quit smoking [48]. Motivational interviewing techniques were the most common psychosocial approach [48, 56, 57, 60–63, 65–67], with five studies combining this with smoking cessation counselling or support [56, 57, 62, 65, 70]. Other approaches included an exercise programme [47], behavioural activation therapy [64], contingency management [71], and adaptations of the National Centre for Smoking Cessation and Training (NCSCT) Standard Treatment Programme [72], the evidence-based framework used in UK stop smoking services to guide structured behavioural support for tobacco dependence (not pregnant specific). Adaptations involved either embedding the NCSCT Programme within a cognitive behavioural therapy framework for understanding the nicotine withdrawal cycle and its impact on mental health [46], or by delivering the programme in a more flexible and supportive manner [69]. One study used proactive outreach calls rather than waiting for patients to initiate contact. The intervention was delivered by a range of professionals, most commonly qualified counsellors [27, 46, 52, 53, 60, 73], followed by research staff with unspecified qualifications [49, 66], smoking cessation counsellors [59, 61],social workers [57], peer researchers [67] and a health/exercise coach [47]. The person delivering the intervention was unclear in two studies [51, 62]. Behaviour change techniques content of the interventions Of the 93 BCTs in the BCT taxonomy v1, 39 were present across included effective trials, 26 of which were identified across more than one included study and therefore classified as ‘promising’ BCTs (Table 2). The most common promising BCTs identified in 10 or more included studies were: goal setting (1.1), problem solving (1.2), action planning (1.4), social support (unspecified) (3.1), Instruction on how to perform the behaviour (4.1), credible source (9.1) and pharmacological support (11.1). Less common BCTs identified in 5–9 included trials were: Self-monitoring of behaviour (2.3), social support (practical) (3.2), social support (emotional) (3.3), information about antecedents (4.2), information about health consequences (5.1), pros and Cons (9.2). Those only identified in one included study were: focus on past success (15.3), mental rehearsal of successful performance (15.2), distraction (12.4), restructuring the social environment (12.2), social reward (10.4), material incentive (10.1), graded tasks (8.7), demonstration of the behaviour (6.1), information about emotional consequences (5.6), feedback on outcome of behaviour (2.7), self-monitoring of outcome(s) of behaviour (2.4), commitment (1.9), discrepancy between current behaviour and goal (1.6) and monitoring of behaviour by others without feedback (2.1). Table 2BCTs identified in included studiesBaker (2006) [60]Brody (2017) [73]Brown (2021) [57]Brunette (2018) [48]Christiansen (2018) [67]Daumit (2023) [66]Gilbody (2019) [69]Hall (2006) [70]MacPherson (2010) [64]Metse (2017) [68]Minami (2022) [71]Patten (2017) [47]Prochaska (2015)Rogers (2018) [49]Stockings (2014) [61]Taylor (20255) [46]Total1.1 Goal setting√√xx√√√√√x√√x√xx101.2 Problem solving√√√x√√√x√x√√xx√√111.4 Action planning√√√x√√√√√xx√√√x√121.5 Review behaviour√xxxx√x√xxxx√xxx41.6 Discrepancy between current behaviour and goal *√xxxxxxxxxxxxxxx11.9 Commitment *xxxxxxx√xxxxxxxx12.1 Monitoring of behaviour by others without feedbackx√xxxxxxxxxxxxxx22.2 Feedback on behaviour√xxxxxx√xxx√√xxx42.3 Self-monitoring of behaviour√x√xx√x√√x√√xxxx72.4 Self-monitoring of outcome(s) of behaviour *xxxxxxxx√xxxxxxx12.6 Biofeedbackx√xxx√√xxxxxxxxx32.7 Feedback on outcomes of behaviour *√xxxxxxxxxxxxxxx13.1 Social support (unspecified)√√√x√√√√√√√√√√√√153.2 Social support (practical)√√xxx√√√x√x√x√√x93.3 Social support (emotional)√xxxxx√xxxx√x√√x54.1 Instruction on how to perform the behaviour√√√√x√√√√√√√√√√√154.2 Information about antecedents√√xxx√x√√xxxxxx√65.1 Information about health consequences√√√√xx√√√√xxxxx√95.6 Information about emotional consequences *xxxxxxxxxxxxxxx√16.1 Demonstration of the behaviour *xxxxxxxxxx√xxxxx15.3 Information about social and environmental consequencesx√x√xxxxxxxxxxxx27.1 Prompts/cues√x√xxxxxxx√xx√xx48.1 Behavioural practice/rehearsalxxxx√√xxxx√√xxxx48.2 Behaviour substitutionxxxxx√√xxxxxxxxx28.7 Graded tasks *xxxxxxxxxxx√xxxx19.1 Credible source√√√√x√√√√√x√x√√√139.2 Pros and cons√xxx√xx√x√xx√xxx510.1 Material incentive (behaviour) *xxxxx√xxxxxxxxxx110.4 Social reward *xxxxxxxxxxx√xxxx111.1 Pharmacological support√√√√√√√√√√√√√√√√1611.2 Reduce negative emotions√xxxx√xxxx√xx√xx412.1 Restructuring the physical environmentx√xxxx√xxxxxxxxx212.2 Restructuring the social environment *xxxxxx√xxxxxxxxx112.3 Avoidance/reducing exposure to cues for the behaviour√√xxx√xxxxxxxxxx312.4 Distraction *x√xxxxxxxxxxxxxx112.5 Adding objects to the environmentxxxx√xxxxx√√xxxx313.2 Framing/reframing√xx√xxxxxxxxxxx√315.1 Verbal persuasion about capabilityxxxx√xxxxxx√x√xx315.2 Mental rehearsal of successful performance*xxxx√xxxxxxxxxxx115.3 Focus on past success*xxxx√xxxxxxxxxxx1*Not present in more than one study therefore not considered promising BCTs identified in included studies *Not present in more than one study therefore not considered promising Comparison to BCTs in the National Centre for Smoking Cessation Training (NCSCT) Programme for pregnant women The promising BCTs identified in this review were mapped against the current NCSCT Standard Treatment Programme (STP) for pregnant women. The analysis revealed a high degree of overlap with the majority of promising BCTs for mental health populations are already embedded within the standard UK pregnancy care pathway. Only one promising BCT identified in this review was absent from the current NCSCT STP for pregnant women: ‘material incentive (behaviour)’ (BCT 10.1). This technique is defined as informing the participant that money, vouchers, or other valued objects will be delivered contingent upon effort and/or progress in performing the behaviour [32]. Risk of bias The majority of studies were judged to be at low risk in most domains. Most studies employed adequate random sequence generation methods [46, 56, 57, 61, 63, 65, 66, 69, 74], although for some other studies, the random sequence generation was unclear [47, 48, 51, 60, 64, 67] (Fig. 2). The majority of studies were rated low risk for allocation concealment [46–48, 51, 54, 56, 57, 61, 62, 68, 69, 74] however, in four studies, it was not clear whether staff and personnel were aware of group assignment during enrolment of participants in the trial [60, 63, 64, 67]. It was not possible to blind participants due to the nature of the intervention and therefore all studies had an ‘unclear’ risk of bias for this domain. One study blinded staff to group assignment [61]. All studies included an objective biochemical measure of point prevalence abstinence and therefore considered to be at low risk of detection bias. Risk of bias In terms of attrition bias, most studies had a low rate of incomplete outcome data although two studies had high dropout rates [61, 68]. Two studies had differential attrition between the two arms adequately [46, 48]. One study had high dropout prior to attending any treatment arm [64]. All studies performed an intention to treat analysis with missing assumed to be smoking which is consistent with the approach in other smoking cessation trials. Most studies reported on the outcomes specific in the methods section and seven studies published a protocol or registered the study prior to publishing the results of the trial [47, 51, 57, 61, 66, 68, 69]. Rogers et al. [74] described a discrepancy between cotinine verified abstinence and self-reported abstinence and yet odds ratios were based only on self-reported abstinence resulting in an unclear rating for selective outcome reporting. Discussion This is the first known study to identify and specify behaviour change techniques from psychosocial smoking cessation interventions for people with mental illness, with the specific aim of identifying which components may help inform or enhance interventions for pregnant women with mental illness. By mapping the active components of effective interventions, 39 of the 93 BCTs in the BCT Taxonomy v1 were identified, 26 of which were considered promising as they appeared in more than one included study. The most consistently observed were pharmacological support (providing or encouraging the use of or adherence to drugs to facilitate behaviour change), instruction on how to perform the behaviour (advising or agreeing on how to perform the behaviour) and social support (unspecified) (advising on, agreeing or providing social support or non-contingent praise or reward for performance of the behaviour). These findings suggest that combining structured behavioural support with credible, relationship-based communication and pharmacological support may be key to promoting engagement and sustained cessation among pregnant women with mental illness. These results provide a foundation for adapting cessation support within perinatal mental health settings, where women may face unique motivational and psychological challenges. Identifying which BCTs are most consistently associated with effectiveness in broader mental health populations offers a practical starting point for tailoring future pregnancy-specific interventions. Most BCTs identified in this review align with the NCSCT Standard Treatment Programme for pregnant women which underpins behavioural smoking cessation support delivered by NHS professionals in England within maternity services. This suggests that the core behavioural framework used by NHS services is comprehensive. Only one BCT within the promising category was not included in the NCSCT Programme: material incentive (behaviour) (10.1) although this is recommended as part of standard care as part of the National Smoke Free Pregnancy Incentive Scheme [75] with a large proportion of maternity trusts currently delivering the scheme across England and the vast majority of pregnant women who smoke are now able to access up to £400 for remaining smoke free throughout pregnancy and 3 months postpartum [75] Understanding how BCTs are operationalised and adapted for pregnant women with mental illness however is likely to be crucial to improving their effectiveness. BCTs may require adaptation in terms of delivery intensity, practitioner support and sensitivity to psychiatry symptoms to achieve the same efficacy seen in the general population. Evidence suggests that people with mental illness are often as motivated to quit as those without [69, 76] yet they face additional psychological, social and structural barriers to cessation, including high nicotine dependence, fear of symptom exacerbation and inconsistent clinical support [77, 78]. Interventions that are individualised, flexible and integrated within mental health care pathways have been shown to improve engagement and abstinence in outcomes in people with severe mental illness [69]. Recent NCSCT guidance for tobacco dependence treatment for people with severe mental illness acknowledges a need for contextual tailoring, recommending approaches that maximise engagement and mitigate barriers among people with severe mental illness who smoke [79]. We do not know how smoking cessation treatment could be optimally tailored for pregnant women with mental illness although some suggestions for treatment tailoring in the above guidance might be appropriate [79]. These include offering both abrupt-quit and gradual-reduction pathways, providing person-centred support that is responsive to mental health fluctuations and incorporating relapse management within treatment plans. Future research should explore how to better support pregnant women with mental illness to stop smoking with a focus on developing and testing interventions which incorporate the promising BCTs identified in this review in ways that are acceptable to women. In terms of clinical practice, findings suggest that smoking cessation support for this group may benefit from greater flexibility, tailoring to both mental health and pregnancy-specific needs and consistent provision of pharmacological support. Our review extends the existing literature by focusing specifically on people with mental illness, aiming to identify which BCTs may be most helpful components to incorporate in interventions for supporting pregnant women with mental illness. It bridges evidence on smoking cessation for those with mental illness with research on cessation support for pregnant women, highlighting BCTs that may be particularly useful for this population. Unlike previous reviews of psychosocial interventions that focus narrowly on severe mental illness [25], this review also includes conditions commonly seen within perinatal mental health services such as post-traumatic stress disorder. The use of the BCT Taxonomy v1 [32] enabled detailed specification of intervention components, providing insights into which techniques may be most useful. Overall, risk of bias of primary trials was low, with biochemical verification of abstinence in all trials, although some studies reported challenges with blinding and attrition. In terms of limitations, this review only included published trials showing effectiveness and it is possible that there were BCTs embedded within complex interventions that overall were not found to be effective but may have been helpful. This is however an established methodology used in several studies for pregnancy smoking cessation and relapse prevention [38, 40, 43] In this review, BCTs were classified as ‘promising’ when they appeared in more than one included trial. While this provides a transparent and replicable approach to identifying commonly used techniques within effective interventions, it does not account for contextual factors, such as population characteristics, delivery format or person or setting that may influence their relevance to pregnant women with mental illness. Alternative approaches, such as weighting BCTs according to effect size, fidelity or contextual fit could provide a more nuanced understanding of which components are most promising for adaptation for pregnant women with mental illness. Finally, no studies specifically targeting pregnant women with mental illness were identified and therefore the relevance of our findings to this population is based on inference from broader mental health populations. However, this review provides an important foundation for identifying, testing, and refining behavioural components in future pregnancy-specific interventions. Conclusion Smoking in pregnancy remains a major preventable cause of maternal and infant mortality and morbidity and disproportionately affects women with mental illness. This review demonstrates that the BCTs effective for smoking cessation in general mental health populations largely align with the current National Centre for Smoking Cessation and Training programme for pregnant women which guides best clinical practice for smoking cessation for pregnant women in the UK. However, how these BCTs are adapted, delivered and perceived by women with mental illness is likely to be critical to their effectiveness. The next phase of our research will use these findings to adapt and further develop an existing intervention specifically for pregnant women who use perinatal mental health services for subsequent evaluation. Supplementary Information Additional file 1. Additional file 2. Acknowledgements Not applicable. Abbreviations Smoking cessation National Centre for Smoking Cessation Training Behaviour change techniques Randomised controlled trials Standard Treatment Programme Authors’ contributions TC, CM, EJ and BT conceived the study. EJ and AC collected and analysed data with support from TC, BT and CM. EJ wrote the manuscript which was edited and revised by all authors. Funding This study was funded by the National Institute for Health Research as part of EJ’s Advanced Fellowship (NIHR302474). TC is an NIHR Senior Investigator. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Data availability The datasets analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study did not include participants and therefore ethical approval was not required. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Additional file 1. Additional file 2. Data Availability Statement The datasets analysed during the current study are available from the corresponding author on reasonable request.